NervGen Pharma Corp. (NASDAQ:NGEN) — Market Cap & Net Worth
Market Cap & Net Worth: NervGen Pharma Corp. (NGEN)
NervGen Pharma Corp. (NASDAQ:NGEN) has a market capitalization of $229.02 Million ($229.02 Million) as of September 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16129 globally and #3829 in its home market, demonstrating a -5.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NervGen Pharma Corp.'s stock price $2.20 by its total outstanding shares 107522633 (107.52 Million). Also see balance sheet size of NervGen Pharma Corp. for a full breakdown of the balance sheet.
NervGen Pharma Corp. Market Cap History: 2026 to 2026
NervGen Pharma Corp.'s market capitalization history from 2026 to 2026. Data shows growth from $236.01 Million to $236.01 Million (0.00% CAGR). Also see NGEN cash generation efficiency for how efficiently the company converts equity into cash flow.
NervGen Pharma Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NervGen Pharma Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check NGEN share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NGEN by Market Capitalization
Companies near NervGen Pharma Corp. in the global market cap rankings as of September 15, 2026. Review how tangible is NervGen Pharma Corp.'s equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to NervGen Pharma Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
NervGen Pharma Corp. Historical Marketcap From 2026 to 2026
Between 2026 and today, NervGen Pharma Corp.'s market cap moved from $236.01 Million to $ 236.01 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $236.01 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of NervGen Pharma Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $229.02 Million USD |
| MoneyControl | $229.02 Million USD |
| MarketWatch | $229.02 Million USD |
| marketcap.company | $229.02 Million USD |
| Reuters | $229.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more